2020 American Transplant Congress » Novel Immunosuppression: Belatacept

3:15pm-3:27pm

Belatacept versus Tacrolimus Combined with Antithymocyte Globulin in Kidney Transplantation

J. Goldman¹, A. Mitrokhin², B. Trivedi¹, V. Vidyasagar¹, N. Vadivel¹, N. Goes³, M. Hart¹

3:27pm-3:39pm

Conversion to Belatacept in HIV(+) Renal Transplant Recipients

A. Santeusanio, A. Bhansali, R. Shapiro, G. De Boccardo

3:39pm-3:51pm

Prospective, Randomized Study of Conversion from Calcineurin Inhibitor (CNI)- to Belatacept (BELA)-Based Maintenance Immunosuppression in Renal Transplant Recipients

K. Budde¹, R. Prashar², H. Haller³, M. Rial⁴, N. Kamar⁵, A. Agarwal⁶, J. de Fijter⁷, L. Rostaing⁸, S. Berger⁹, A. Djamali¹⁰, N. Leca¹¹, L. Allamassey¹², S. Gao¹², M. Polinsky¹², F. Vincenti¹³

3:51pm-4:03pm

Three Year Post Co-Stimulation Blocking Agent (Belatacept) Switch Outcomes of Kidney Transplant Patients Diagnosed with Post-Transplant Thrombotic Microangiopathy

A. Gamilla-Crudo, S. Hussain, A. Rizvi, R. Ramirez, M. Kueht, H. Stevenson-Lerner, J. Fair, M. Mujtaba

4:03pm-4:15pm

Belatacept-Based, Calcineurin Inhibitor and Corticosteroid Free Immunosuppression: Differential Outcomes Based on Recipient Age

N. Wilson¹, A. R. Shields², D. Kaufman³, A. Wiseman⁴, A. L. Christianson¹, S. Tremblay¹, J. P. Leone⁵, A. J. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹

4:15pm-4:27pm

Belatacept Conversion: Are Patients BENEFIT-ing

R. Crew, S. Mohan, S. S. Patel

4:27pm-4:39pm

Conversion to a Belatacept Based Immunosuppression Regimen in Renal Transplant Recipients

K. Paplaczyk, K. Cunningham, C. D'Agostino, D. Pinelli, J. Schulte, A. Shetty